Flagship drug wins PBS expansion

Posted 31 March 2025 AM

Boehringer Ingelheim's flagship product, Jardiance, has been significantly expanded under the PBS with the eligible patient population growing by an additional 115,000 Australians.

From 1 April, the SGLT-2-inhibitor will be reimbursed for use, right from the start with metformin in patients with type 2 diabetes who are at high cardiovascular risk, have existing cardiovascular disease or identify as Aboriginal or Torres Strait Islander – regardless of their HbA1c level.

To see the whole article, please login